Wednesday's Health Winners & Losers
Boston Scientific (BSX) rose 3% to $17.23 after the company said 5,000 patients have now been treated with its Precision Spinal Cord Stimulation System, a rechargeable shocking device to treat chronic pain. The company is slated to report its quarterly earnings on Thursday.
Bovie Medical's (BVX) shares gained ground after the company announced it received Food and Drug Administration marketing approval for a suture-removal device for human, as well as animal, medical procedures. Shares were up 3.8% to $8.50.
Shares of DOV Pharmaceutical (DOVP) rose on positive results of an early trial on its experimental painkiller bicifadine. The drug didn't show signals of possibly causing cancer in rats or mice over two years. "This timeframe is accepted as analogous to administering the drug over a lifetime in humans," the company said in a press release. Shares of DOV were up 4.3% to $1.96.
Alnylam Pharmaceuticals' (ALNY) shares fell 1.6% to $12.40 after the company reported a wider-than-expected net loss in the second quarter.The company lost $9.9 million, or 31 cents a share in the quarter, including $1.6 million, or 5 cents a share, in stock-based compensation expenses, compared with a loss of $11.1 million, or 54 cents a share, a year ago. Analysts were expecting the company to lose 28 cents a share. Revenue in the second quarter exceeded expectations, reaching $6 million vs. analysts' estimates of $5.6 million. Aspect Medical Systems (ASPM), a maker of anesthesia-monitoring systems, sank 14.9% to $15.66, despite better-than-expected earnings in the second quarter. The company earned $2.1 million, or 9 cents a share, compared with $1.6 million, or 7 cents a share, last year. Excluding stock-based compensation expenses, the company earned 16 cents a share, compared with analysts' expectations of 14 cents. Aspect's sales were up 21% to $22.6 million in the quarter. The company's third-quarter guidance was lower than analysts were expecting, however. In its earnings report, the company said it expects to earn 14 cents to 16 cents a share on sales of $22 million to $22.8 million. Analysts surveyed by Thomson First call were expecting earnings of 16 cents a share in the third quarter on sales of $24.1 million.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV